Deacetyl lanolin injection

1. Positive inotropic effect: This product selectively binds to the Na-KATPase of the myocardial cell membrane and inhibits the activity of the enzyme, causing damage to the active coupled transport of Na-K inside and outside the myocardial cell membrane, and increasing the concentration of Na in myocardial cells, thereby activating the exchange of Na and Ca2 on the sarcolemma, increasing the amount of Ca2 in the cytoplasm, and increasing the Ca2 reserve in the sarcoplasmic reticulum. When the myocardium is excited, more Ca2 is released; the increase in the concentration of Ca2 in myocardial cells excites myocardial contractile proteins, thereby increasing myocardial contractility; 2. Negative frequency effect: Due to its positive inotropic effect, it increases the cardiac output of the failing heart, improves the hemodynamic state, eliminates the reflex increase of sympathetic nerve tension, and enhances the vagus nerve tension, thereby slowing down the heart rate and delaying atrioventricular conduction. In addition, at low doses, it increases the sensitivity of the sinoatrial node to vagus nerve impulses, which can enhance its effect of slowing down the heart rate. Due to its negative frequency effect, the diastole period is relatively prolonged, which is beneficial to increase myocardial blood supply; large doses (usually close to the toxic dose) can directly inhibit the sinoatrial node, atrioventricular node and His bundle to present sinus bradycardia and varying degrees of atrioventricular conduction block; 3 Cardiac electrophysiological effects: through direct effects on myocardial electrical activity and indirect effects on the vagus nerve, it reduces the autonomy of the sinoatrial node; improves the autonomy of Purkinje fibers; slows down the conduction velocity of the atrioventricular node, prolongs its effective refractory period, and leads to an increase in latent conduction of the atrioventricular node, which can slow down the ventricular rate of atrial fibrillation or atrial flutter; since this drug shortens the effective refractory period of the atrium, when used for atrial tachycardia and atrial flutter, it may lead to acceleration of the atrial rate and conversion of atrial flutter to atrial fibrillation; shortens the effective refractory period of Purkinje fibers.

Main ingredients: 3-[(0-beta;-D-glucopyranosyl-(1rarr;4)-0-2,6-dideoxy-beta;-D-ribo-hexopyranosyl-(1rarr;4)-0-2,6-dideoxy-beta;-D-ribo-hexopyranosyl-(1rarr;4)-0-2,6-dideoxy-beta;-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-cardiosteroid-20(22)-enolactone. Molecular formula: C47H74O19 Molecular weight: 943.09

This product is a colorless clear liquid.

It is mainly used for heart failure. Due to its rapid action, it is suitable for patients with acute heart failure or acute exacerbation of chronic heart failure. It can also be used to control the ventricular rate of patients with atrial fibrillation and atrial flutter accompanied by rapid ventricular rate. It is slow to take effect in terminating tachycardia and is rarely used.

Common dosage for intravenous injection in adults: dilute with 5% glucose injection and slowly inject, the first dose is 0.4-0.6 mg, and then 0.2-0.4 mg can be given every 2-4 hours, with a total of 1-1.6 mg. Common dosage for children: divided into 2-3 doses with an interval of 3-4 hours according to the following doses. For premature infants and full-term newborns or children with renal function impairment and myocarditis, intramuscular or intravenous injection is 0.022 mg/kg body weight; for 2 weeks to 3 years old, it is 0.025 mg/kg body weight. After satisfactory therapeutic effect is obtained by intravenous injection of this product, the commonly used maintenance dose of digoxin can be used to maintain the therapeutic effect.

1 Common adverse reactions include: new arrhythmias, poor appetite or nausea, vomiting (stimulation of the medullary center), lower abdominal pain, abnormal weakness, and softness; 2 Rare reactions include: blurred vision or yellow vision (symptoms of poisoning), diarrhea, and central nervous system reactions such as depression or confusion; 3 Rare reactions include: drowsiness, headache, rash, and urticaria (allergic reactions); 4 Among the manifestations of digitalis poisoning, arrhythmias are the most important, and the most common is ventricular premature beats, accounting for about 33% of cardiac reactions. The second is atrioventricular block, paroxysmal or accelerated junctional tachycardia, paroxysmal atrial tachycardia with atrioventricular block, ventricular tachycardia, sinus arrest, ventricular fibrillation, etc. Arrhythmias are more common in children than other reactions, but ventricular arrhythmias are less common than in adults. Newborns may have a prolonged PR interval.

1. Poisoning by any cardiac glycoside preparation; 2. Ventricular tachycardia, ventricular fibrillation; 3. Obstructive hypertrophic cardiomyopathy (can still be considered if accompanied by systolic dysfunction or atrial fibrillation); 4. Preexcitation syndrome with atrial fibrillation or flutter.

1. When used together with amphotericin B, corticosteroids or potassium-losing diuretics such as bumetanide (the product is buturamine) and ethacrynic acid (ethacrynic acid), it can cause hypokalemia and lead to digitalis poisoning; 2. When used together with antacids (especially magnesium trisilicate) or antidiarrheal adsorbents such as white clay, pectin, cholestyramine (cholestyramine) and other anion exchange resins, sulfasalazine or neomycin, and aminosalicylic acid, it can inhibit the absorption of digitalis cardiac glycosides and lead to a weakening of the effect of cardiac glycosides; 3. When used together with antiarrhythmic drugs, calcium salt injection 1. When this product is used together with narcotics, cocaine, pancuronium bromide (Pancuronium Bromide, Pancoron, Bahuolang), rauwolfia alkaloids, succinylcholine (Sceline; Suxamethonium Chloride) or adrenergic drugs, arrhythmias may occur due to additive effects; 2. Digitalized patients with severe or complete atrioventricular block and normal blood potassium should not use potassium salts at the same time, but when thiazide diuretics are used together with this product, potassium salts are often required to prevent hypokalemia; 3. The use of beta-receptor blockers with this product may cause severe bradycardia due to atrioventricular block, which should be taken seriously. But it does not rule out the use of beta-blockers for supraventricular tachyarrhythmias where digitalis cannot control the ventricular rate; 6. When used together with quinidine, the blood concentration of this product can be increased by about one-fold. The degree of increase is related to the dosage of quinidine and can even reach toxic concentrations. Even if digoxin is discontinued, its blood concentration continues to rise. This is because quinidine replaces digoxin from tissue binding and reduces its distribution volume. When the two drugs are used together, the dosage of digoxin should be reduced by 1/2-1/3; 7 When used together with verapamil, diltiazem, and amiodarone, the blood concentration of digoxin can be increased due to the reduction of the renal and systemic clearance rate of digoxin, which can cause severe bradycardia; 8 Spironolactone can prolong the half-life of this product, and the dose or dosing interval needs to be adjusted, and the blood concentration of this product should be followed up and monitored; 9 Angiotensin converting enzyme inhibitors and their receptor antagonists can increase the blood concentration of this product; 10 Edrophhoniumchloride (EdrophoniumChloride, Tensilon) and this product can cause obvious bradycardia when used together; 11 Indomethacin (Indometacin) 12. When used with heparin, the dosage of heparin should be adjusted because this product may partially offset the anticoagulant effect of heparin. 13. When using magnesium sulfate intravenously during digitalization, extreme caution should be exercised, especially when calcium salts are also injected intravenously, as heart block may occur. 14. Erythromycin can increase the absorption of this product in the gastrointestinal tract due to changes in gastrointestinal flora. 15. Metoclopramide (Maxolon) reduces the bioavailability of digoxin by about 25% due to promoting intestinal motility. Propane increases the bioavailability of digoxin by about 25% due to inhibiting intestinal peristalsis. 16. It is forbidden to be used with calcium injection. 17. It should not be used in combination with acids or bases.

Keep away from light and store in a sealed container.

2ml:0.4mg

Chengdu Brilliant Pharmaceutical Co., Ltd.

• Founded in:

  1995-10-10

• Address:

  No. 263, Hexiang 3rd Street, Chengdu Hi-tech Zone

• Tax NO.:

  91510100633104205M

• Registered Funds:

  450 million yuan

• Website:

  Log in to view

• Email:

  Log in to view